WT Faba Catalyst: Bridging Science and Business in Life Sciences WT Faba Catalyst, a pioneering initiative of the ‘Whale Tank FABA Life Science Fund’, is redefining how Indian innovation in life sciences reaches global markets. Born from the vision of seasoned veterans and mission-driven leaders, it provides not just capital—but clarity, confidence, and capability—to life science startups poised to transform human health, agriculture, and nutrition. With ‘strategic partnerships’ that already include Revelations Biotech’, ‘ATGC Biotech’, and ‘Utopia Therapeutics’, Whale Tank has become a cornerstone of support for startups navigating the demanding path from the lab bench to the marketplace. **Our Origin Story: Built by Experts, For Innovators** Whale Tank was founded by a group of **industry veterans** with a shared mission: **to resolve the systemic challenges faced by deep-science startups** in India and the global South. From their work in pharma, agritech, biotech, and venture capital, these leaders understood a core reality—**innovation alone isn’t enough**. Scientific breakthroughs often stall due to fragmented business planning, unclear market access, and limited investor guidance. To change this narrative, Whale Tank was established as a **science-first catalyst** with business-savvy DNA, offering tailored support to help life sciences ventures scale impact and unlock commercial potential. — ### **Strategic Partnerships that Amplify Innovation** Whale Tank doesn’t just fund ideas—it backs missions. Our growing portfolio features strategic collaborations with: #### **Revelations Biotech** An innovative force in **natural sweeteners and prebiotics**, Revelations is redefining food and nutrition science with cutting-edge products like **Fructooligosaccharides (FOS)**, **Brazzein**, and **Allulose**. Whale Tank invested $2 million in this high-growth venture, facilitating: – Global partnerships with **Kellogg’s**, **PepsiCo**, **Nestlé**, **Britannia**, and **Unilever** – Scale-up of production infrastructure (fermentation and spray-drying facilities) – Market penetration across **North America**, **Europe**, and **Asia-Pacific** Revelations reflects Whale Tank’s belief that **science-driven startups can reshape public health, when supported with strategic capital and mentorship**. #### **ATGC Biotech** As a biotechnology pioneer in **sustainable agriculture and pest management**, ATGC has developed eco-friendly technologies that improve crop yields while minimizing environmental impact. Under the leadership of **Dr. Markandeya Gorantla** and **Rolando Alegria**, ATGC: – Specializes in bio-rational solutions using behavioral ecology using pheromone based mating disruption technology – Has filed multiple patents and gained regulatory approvals – Has scaled distribution through private sector and public procurement models Whale Tank and ATGC share a common DNA: commitment to **science-backed sustainability** and **farm-to-fork innovation**. #### **Utopia Therapeutics** Founded by **Dr. Uday Saxena**, Utopia is a drug discovery and therapeutics startup with a focus on **neurodegenerative and metabolic disorders**. Utopia’s leadership—rooted in big pharma —guides startups in navigating clinical validation, regulatory frameworks. Whale Tank’s synergy with Utopia provides its portfolio companies with strategic insights into **drug development lifecycles**, **FDA compliance**, and **venture pathways. — ### **Mission-Driven Investment Philosophy** At its core, **Whale Tank is a catalyst, not just a fund**. Our mission is to: – **Fuel Innovation** through strategic, milestone-based capital – **Bridge Science and Business** with real-world execution models – **Accelerate Commercialization** across agriculture, biotech, diagnostics, and therapeutics – **Empower Indian Science** by building platforms for global impact We understand that scientific excellence must be matched with **business discipline** and **market readiness**—so we provide both. — ### **Our Values: The Whale Tank Ethos** Our approach is guided by unwavering principles that reflect our commitment to lasting impact: #### Integrity as a Foundation of Trust We uphold the highest standards of transparency and ethical governance, ensuring alignment between founders, investors, and stakeholders. #### Collaboration for Greater Innovation We believe that breakthrough ideas flourish in collaborative ecosystems. Whale Tank connects innovators with world-class mentors, global partners, and technical experts to foster innovation at scale. #### Commitment to Continuous Improvement The life sciences landscape evolves fast—and so do we. From regulatory updates to tech advancements, we equip our portfolio with the latest tools to stay competitive and compliant. — ### **Our Differentiators: The Whale Tank Advantage** Whale Tank delivers a full-spectrum support model that integrates: | Service | Description | |——–|————-| | **Visionary Capital** | Flexible seed and Series A funding, aligned to product-market readiness | | **Mentorship Network** | Access to 50+ domain experts in biotech, drug development, clinical trials, and regulatory science | | **Business Alchemy** | Go-to-market, licensing, pricing, and distribution support | | **IP & Legal Advisory** | End-to-end guidance on patents, exclusivity, and data rights | | **Infrastructure Scaling** | Support for facility design, tech transfer, and manufacturing scale-up | | **Exit Strategy Navigation** | IPO prep, M&A, and secondary share sale pathways | This framework has empowered startups to **reduce time-to-market**, **attract global partners**, and **build sustainable revenue models**. — ### **Governance, Structure & Investor Value** ### **Impact Snapshot: Delivering Results that Matter** Beyond numbers, our true impact is in lives touched, diseases addressed, and ecosystems enhanced. Whether it’s **healthy nutrition**, **sustainable farming**, or **precision medicine**, Whale Tank empowers science that serves society. — ### **Vision for the Future: Scaling Science for Global Good** Whale Tank is now building a **pipeline of next-gen ventures** across: – **Synthetic Biology** – **Microbiome Therapeutics** – **Agricultural Biocontrols** – **Climate-Resilient Crop Technologies** – **Affordable Diagnostics and Functional Foods** Our goal is to create **India’s first science-forward unicorns** that are not just financially successful—but mission-aligned and globally relevant. — ### **Join the Movement: Let’s Build the Future of Life Sciences** We invite researchers, entrepreneurs, and investors to partner with us. Whether you’re developing the next sugar alternative, breakthrough therapy, or agricultural bioinnovation—**Whale Tank will help you get there.** For partnerships and investment inquiries, contact: **Dr. Jagadeesh Gandla** Chief Operating Officer, Whale Tank FABA Life Science Fund **info@whaletank.in** — **WT Faba Catalyst isn’t just a fund. It’s a movement.** A movement to **empower ideas**, **bridge discovery with delivery**, and **build India’s life sciences future**—one transformative startup at a time. Let’s catalyze the change.
Viruj Group
Viruj Group was established in 2014 by a group of young & experienced professionals with the specific objective to develop & produce complex, small to large volume, technology driven Intermediates/ API at competitive prices, thus providing the critical India advantage for a CRO/ NCE Molecules across the world. We are a partner for various Innovator companies to supply High Quality API’s /Intermediates & Fine chemicals at competitive prices Complying with Regulatory Requirements. Our Experienced R&D team – well qualified & equipped to develop most complex Intermediates/ APIs and expertise to handle wide range of chemical reactions. Manufacturing capabilities ranging from gram level to multiple ton lots. Strong Intellectual Property Management and Regulatory back up & Absolute assurance of best quality APIs. Expertise in the development of novel, non-infringing and cost-effective API’s Speed to market for customers and support the NCE / Dossier by time bound development. Timely delivery and prompt response to all queries of the customers CRO/CDMO – We intend to take up any projects in this area working closely with you team for small or big enquiries, we have a dedicated team working in this area. Flow Chemistry – Our process lab is established with a motto to make API / Intermediates and Fine Chemicals in Flow chemistry mode as far as the molecule permits, we have established few global business and making R&D/ Pilot scale modules and converting existing batch chemistry to flow chemistry way. We are ready to take up projects for any commercial scale products on Pharma/ Agro/Fine Chemicals space.
UDELA
Udelá is a regulatory consulting company. Udelá was created by a group of highly qualified professionals in the regulatory affairs field, with more than 15 years of experience, for medicines, medical devices, food, dietary supplements and cosmetics. Udelá is located in Mexico City, and has presence in Central and Latin America. Objectives – Provide technical and regulatory support, which accelerates the access of medicines, medical devices, food, dietary supplements and cosmetics on the market to improve the health of the population, through regulatory standard compliance and a build trust with regulatory agencies. – Bridge the knowledge gap of our clients in regulatory affairs to improve the communication with the regulatory agencies – Enhance processes of marketing authorization of medicines and medical devices (pre-marketing, registration and post marketing) to ease the access on the market and improve its maintenance – Active collaboration with our clients to generate better regulatory strategies to reduce timelines and optimize resources Services – Dossier compilation and evaluation o Medical Devices o New chemical entities/ New Molecules o Generics / Hybrids o Biotechnological products and Biosimilars o Vaccine o Biologics and blood derivative products – Design of regulatory strategies o Regulatory Due diligence o Feasibility studies for medicines and medical devices registration o Strategies for maintenance of existing and forthcoming products – Hosting & Testing services – Good manufacturing practices / License – Advertising – Translations – KOL feedback | At Udelá, we empower healthcare companies—whether local or international, emerging or established—to enter and expand in the complex markets of Mexico and Latin America. With over 5 years of experience, we specialize in regulatory intelligence, market entry strategies, and end-to-end support for pharmaceutical products, biotechnology, medical devices, cosmetics, food supplements, and more. We understand that navigating the ever-evolving regulatory frameworks of Latin American countries can be overwhelming if not approached strategically. That’s where we come in. Our multidisciplinary team of consultants combines in-depth knowledge of regional regulatory environments with strategic execution capabilities. We act with precision, pragmatism, and agility to deliver timely and compliant market access solutions. Our key services include: Regulatory and strategic consulting for healthcare products Legal representation and in-country regulatory agent services Warehousing and distribution infrastructure compliant with national regulations With headquarters in Mexico City and operations in Colombia, Brazil, Chile, Perú, Ecuador, Uruguay, Paraguay, Bolivia, Argentina and Central America, we offer both local expertise and regional reach. Whether you’re launching a generic, innovative, or biologic product—or seeking to expand your presence across LATAM—Udelá is your trusted partner in achieving regulatory clarity and commercial success. Where do you want to go next? Let’s go beyond, together.
SyntheticGestalt KK
“DRUG DISCOVERY REIMAGINED: 90% LESS COST, 75% LESS TIME” [PIONEERING MOLECULAR AI INNOVATION] SyntheticGestalt has developed the world’s largest molecule-specialized AI foundation model, revolutionizing drug discovery and molecular design across industries. Founded in 2018 in Tokyo, we’re addressing a critical challenge: early-stage pharmaceutical R&D consumes 40% of total drug development costs while traditional AI approaches struggle with limited datasets and technical barriers. Our proprietary SG4D10B foundation model, trained on 10 billion compounds across 100+ tasks, captures four-dimensional molecular information for unprecedented prediction accuracy. Unlike repurposed language models, our architecture was built specifically for molecular science, delivering superior performance even with minimal training data. [PROVEN RESULTS ACROSS INDUSTRIES] Our technology has delivered transformative ROI through real-world applications: * Pharmaceutical Partners: Virtual screening of 38 billion compounds identified a novel MKNK2 inhibitor in just 3 months instead of 12, with 90% cost reduction * Beverage Industry: Reduced discovery timelines for functional ingredients from 5 years to 6 months, identifying 10 active candidates from a 250M compound library * Environmental Solutions: Discovered novel PET-degrading enzymes outperforming existing plastic recycling solutions Chemical Manufacturing: Identified enzymatic pathways enabling sustainable production processes These successes demonstrate our consistent ability to accelerate molecular discovery by 75% while reducing costs by 90% compared to traditional approaches. [FLEXIBLE BUSINESS MODELS] SyntheticGestalt offers engagement options tailored to client needs: * Foundation Model Access: Enterprise subscription to SG4D10B via AWS and Google Cloud Marketplaces * Strategic Research Collaborations: Fixed-fee discovery programs or milestone-based development partnerships * Compound Discovery: Direct IP transfer of novel molecules identified through our AI platform Our multidisciplinary team of AI experts, medicinal chemists, and computational biologists works directly with partners to maximize value delivery. [UNIQUE TECHNOLOGY ADVANTAGES] What sets our approach apart: * World’s Largest Molecular AI: Trained on 10 billion compounds—orders of magnitude beyond competitors * True 4D Representation: Captures complete structural and electronic properties for superior prediction accuracy * Minimal Data Requirements: Achieves high performance with significantly smaller datasets than traditional AI * Cross-Domain Applications: From small molecule drugs to industrial enzymes, materials, and beyond [APPLICATIONS BEYOND PHARMACEUTICALS] While pharmaceutical applications deliver dramatic ROI, our technology drives innovation across multiple industries: * Chemical Manufacturing: Enzyme discovery for greener production processes * Materials Science: Novel materials with precisely engineered properties * Agrichemicals: Safer, more effective crop protection solutions * Food & Beverage: Functional ingredients with targeted properties * Fragrance: Prediction of sensory characteristics in aroma compounds [GLOBAL EXPANSION] With successful partnerships in Japan with major corporations including Enamine and Asahi Group, we’re now expanding internationally, raising Series B funding to accelerate U.S. market entry. Our vision extends to designing multi-component molecular systems, optimizing synthetic pathways, predicting complex biological interactions, and creating autonomous discovery platforms—dramatically accelerating scientific innovation. [PARTNER WITH US AT BIO INTERNATIONAL 2025] Visit us at Booth #2265 in the Japan Pavilion or schedule a meeting through the BIO Partnering System to discuss: * How our technology can transform your specific R&D challenges * Collaborative research opportunities * Foundation model access options Join the organizations already leveraging our technology to achieve breakthrough results in molecular discovery with 90% less cost and 75% less time. [CONTACT INFORMATION] Location: Japan Pavilion, Booth #2265 Website: https://syntheticgestalt.com/en Email: d.morohashi@syntheticgestalt.com Partnering Contact: Daisuke Morohashi, Head of AI Business
Stämm
Stämm is an international biotechnology company that is revolutionizing the way biomanufacturing is done. Founded in 2016, it’s now based in the United States and has offices and labs in Argentina and Switzerland. The company offers advanced solutions for automated, continuous, and improved biologics & cell therapies production with a wide range of solutions that stem from their core solution, the Bioprocessor, to cell line development and an AI transomics platform. Stämm’s mission is to make bioprocesses easy, scalable, sustainable and repeatable inspired by nature’s solutions, unleashing the full potential of biotechnology and thus freeing their partners to focus on the disruptive discoveries that make an impact in people’s lives. The company is committed to providing the best possible solutions to accelerate life-changing therapies through flexible, future-ready facilities that meet the evolving needs of its clients and improve global health. Products & Services Stämm’s products and services are structured in three segments: 1. Biomanufacturing: Stämm’s core solution is a continuous, bubble-free Bioprocessor, a biomanufacturing platform with a novel 3D printed bioreactor that enhances yields, reduces costs, and minimizes footprint and energy consumption. Stämm’s approach enables a scalable,energy-efficient solution that provides an ideal cell growth environment. 2. Bio AI: Stämm is developing a transomics platform that leverages in-silico methods through their Multi-omic Network Atlas (MoNA™) allowing to map the biomolecular behaviour of cells with its experimental ambient conditions. With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet-lab assay design, execution and interpretation. Therefore achieving high precision biomolecular decision-making. 3.Bioenegineering: Stämm is developing state-of-the-art devices for Cell Line Development with automated cell engineering, clone outgrowth & screening for production of biologics. This is being done through a Bioengineering Platform, an engineering and sorting platform powered by a high-throughput automated system to streamline your workflow and a Clone Selection Platform, a specialized solution that automates clone selection and screening, monitoring the process to optimize your pipeline. Stämm’s is committed to providing a bio-innovative perspective capable of tackling the entire biomanufacturing pipeline
Setsuro Tech Inc.
Setsuro Tech Inc. is a biotech startup that originated from Tokushima University and was founded in 2017. The company’s mission is to “create industries that solve your and the planet’s problems by harnessing from the potential of living organisms”. Our company provides innovative genome editing technology and contributes to the advancement of industry and human health and well-being. We use proprietary technologies to provide contract genome editing R&D services to researchers in academia and industry. Our goal is to provide genome-edited organisms broadly available to society and to advance the genome editing industry. The name of our service, PAGEs, stands for Platform App(lication) using Genome Editing by Setsuro Tech. We named it with the idea that “genome editing will add new pages to all industries worldwide and bring about a revolution in the genome editing industry”. With PAGEs, Setsuro Tech’s genome editing technology can be used to develop new traits in a wide range of species and produce useful and valuable substances. Regardless of the size of the company or the scope of the business or industry, Setsuro Tech’s PAGEs are creating breakthroughs in current production systems and providing solutions to social and environmental problems.
Sante Science
Sante Science is a biotech/foodtech that has developed an innovative biotechnology through upcycling to produce natural ingredients that enhance treatment and reduce the oncological chemotherapy side effects in pets and humans, improving quality of life, longevity, gut and immune health.
Osborne Clarke
Osborne Clarke is an international legal practice with over 2,800 employees at 26 locations worldwide. With the claim “Helping you succeed in tomorrow’s world”, extensive industry knowledge in the Life Sciences and Healthcare industry and outstanding expertise in the digital transformation of business models, Osborne Clarke advises and represents companies, entrepreneurs and investors in all practical business law issues focusing not only on our chosen sectors but also on the three key topics of digital transformation, decarbonisation and urban dynamics.
Leeuwenhoek Laboratories Co., Ltd.
Leeuwenhoek Laboratories Co., Ltd., based in Taiwan, is at the forefront of precision health and next-generation probiotic research. We have established a comprehensive Akkermansia muciniphila (AKK) bioresource, which includes 112 bacterial strains, a whole-genome sequence database, a MALDI-TOF mass spectrometry database, and a metabolomics database. This pioneering initiative enables the development of innovative probiotic and synbiotic products. Leveraging this extensive bioresource, we have successfully developed a series of AKK strains specifically designed to target metabolic-associated diseases. Our research also focuses on scientifically validated functional metabolites and proteins produced by AKK, which play a crucial role in promoting human health. Additionally, we have developed a gut microbiome metabolomics database, providing advanced, data-driven insights into gut health. By integrating cutting-edge metabolomics profiling with biotechnological advancements, we develop clinically supported synbiotic formulations designed to enhance intestinal homeostasis, boost GLP-1 secretion, improve metabolic health, and support overall well-being. Committed to scientific rigor and innovation, Leeuwenhoek Laboratories continues to drive breakthroughs in next-generation probiotics, paving the way for precision and personalized health solutions.